

BUYTP: Rs 455 | ▲ 16%

INDRAPRASTHA GAS

Oil & Gas

07 November 2019

Margins expand, volume growth robust

Indraprastha Gas' (IGL) Q2FY20 EBITDA was above estimates at Rs 3.9bn (+27.5% YoY; Rs 6.5/scm). Volumes at 6.6mmscmd (+11.6% YoY) were in line as CNG/PNG sales grew 10.3%/11.8% YoY. EBITDA margin expansion stemmed from price hikes across products in Jul/Aug'19, in anticipation of INR weakness. IGL's margins still trend well below its CGD peers with a similar volume mix. We maintain our earnings estimates and Sep'20 DCF-based target price of Rs 455.

Rohit Ahuja | Harleen Manglani research@bobcaps.in

Volume growth remains robust: IGL's volume growth is trending in line with its long-term average (~10%). CNG volumes remain strong (+10% YoY) and could sustain as the company expands CNG stations on national highways. PNG growth was driven by steady expansion in the industrial segment (+14% YoY), while domestic volumes surged as well (+22% YoY).

Margin expansion looks sustainable: EBITDA margins improved to Rs 6.5/scm in Q2, but still trend below CGD peer MAHGL (Rs 10/scm in Q1) and its JV subsidiary MNGL (~Rs 9/scm in FY19). Sustained low spot LNG prices and the cut in domestic gas prices from Oct'19 make a favourable case for IGL to sustain margins.

New areas offer near-term volume traction: IGL's management stated that annual capex could be raised to ~Rs 11bn (from Rs 6bn) as the company's CGD network is expanded into new areas. We estimate ~3mmscmd of volume potential from geographical areas (GA) in Uttar Pradesh – Meerut, Muzaffarnagar, Kanpur – and others such as Karnal and Ajmer. Management sees no immediate threat to volume growth from electric vehicles, as three-wheelers (~15% of CNG demand) are likely to form the bulk of EV conversions in the initial stage.

Ticker/Price	IGL IN/Rs 393
Market cap	US\$ 3.9bn
Shares o/s	700mn
3M ADV	US\$ 8.4mn
52wk high/low	Rs 396/Rs 241
Promoter/FPI/DII	45%/23%/32%

Source: NSE

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	45,921	57,648	65,585	77,866	91,746
EBITDA (Rs mn)	11,144	12,570	15,020	16,919	19,417
Adj. net profit (Rs mn)	7,217	8,739	11,396	13,302	16,210
Adj. EPS (Rs)	10.3	12.5	16.3	19.0	23.2
Adj. EPS growth (%)	19.0	21.1	30.4	16.7	21.9
Adj. ROAE (%)	21.7	21.7	23.3	22.2	22.1
Adj. P/E (x)	38.1	31.5	24.2	20.7	17.0
EV/EBITDA (x)	24.2	21.5	18.0	15.6	13.1

INDRAPRASTHA GAS



FIG 1 - QUARTERLY PERFORMANCE

(Rs mn)	Q2FY20	Q2FY19	Y ₀ Y (%)	Q1FY20	Q ₀ Q (%)	H1FY20	H1FY19	Y ₀ Y (%)
Net sales	16,925	14,215	19.1	15,761	7.4	32,557	27,089	20.2
Raw Material Consumed	9,905	8,425	17.6	9,217	7.5	19,122	15,842	20.7
% of sales	58.5	59.3	-	58.5	-	58.7	58.5	-
Other expenditure	3,093	2,710	14.1	2,960	4.5	6,053	5,216	16.0
% of sales	18.3	19.1	-	18.8	-	18.6	19.3	-
EBITDA	3,926	3,080	27.5	3,585	9.5	7,382	6,031	22.4
EBITDA (Rs/scm)	6.5	5.7	14.2	6.3	3.0	6.3	5.8	9.2
EBITDA margin (%)	23.2	21.7	-	22.7	-	22.7	22.3	-
Depreciation and amortisation	621	503	23.5	605	2.8	1,226	976	25.7
Interest	18	6	223.2	16	11.0	34	11	207.1
Other income	390	332	17.5	354	10.1	744	594	25.2
Profit Before Tax	3,677	2,903	26.6	3,318	10.8	6,865	5,638	21.8
Provision for tax	(133)	1,030	(112.9)	1,134	(111.8)	1,001	2,006	(50.1)
PAT	3,115	1,873	66.3	2,184	42.6	5,864	3,632	61.5
Profit from associates	424	235	80.6	336	26.3	760	425	78.9
Consolidated PAT	3,539	2,108	67.9	2,520	40.5	6,625	4,057	63.3
NPM (%)	18.4	13.2	-	13.9	-	18.0	13.4	-
Standalone EPS (Rs)	4.4	2.7	66.3	3.1	42.6	8.4	5.2	61.5
Consolidated EPS (Rs)	5.1	3.0	67.9	3.6	40.5	9.5	5.8	63.3

Source: Company, BOBCAPS Research

FIG 2 - SEGMENT-WISE VOLUME BREAKUP

	Q2FY20	Q2FY19	Y ₀ Y (%)	Q1FY20	Q ₀ Q (%)	H1FY20	H1FY19	Y ₀ Y (%)
CNG Volume (mn kg)	320	290	10.3	305	4.9	625	563	11.0
PNG Volume (mmscm)	152	136	11.8	145	4.8	297	265	12.1
Industrial/Commercial	73	64	14.1	68	7.4	141	122	15.6
Domestic	33	27	22.2	31	6.5	64	54	18.5
Natural Gas	46	45	2.2	46	-	92	89	3.4
Total Volume (mmscm)	605	542	11.6	569	6.3	1,174	1,047	12.1
Total Volume (mmscmd)	6.58	5.89	11.6	6.25	5.2	6.42	5.72	12.1


Source: Company, BOBCAPS Research

FIG 3 - OPERATING PERFORMANCE

	Q2FY20	Q2FY19	Y ₀ Y (%)	Q1FY20	Q ₀ Q (%)	H1FY20	H1FY19	Y ₀ Y (%)
Avg realisation (Rs/scm)	28.0	26.2	6.7	27.7	1.0	27.7	25.9	7.2
Gas cost (Rs/scm)	16.4	15.5	5.3	16.2	1.1	16.3	15.1	7.6
Gross spreads (Rs/scm)	11.6	10.7	8.6	11.5	0.9	11.4	10.7	6.5
CNG realisation (Rs/kg)	45.5	40.5	12.4	43.9	3.6	44.4	40.0	11.2
PNG realisation (Rs/scm)	27.0	28.7	(5.8)	27.4	(1.6)	27.8	27.6	0.7
EBITDA (Rs/scm)	6.5	5.7	14.2	6.3	3.0	6.3	5.8	9.2
Other operating costs	5.1	5.0	2.2	5.2	(1.7)	5.2	5.0	3.5




FIG 4 - CND AND PNG GROWTH




Source: Company, BOBCAPS Research

FIG 5 - CNG AND PNG REALISATION



Source: Company, BOBCAPS Research

FIG 6 - CNG AND PNG VOLUMES





Valuation methodology

At 17x FY22E EPS, IGL's valuations look demanding. In our view, robust volume growth visibility (over 3-5 years) coupled with EBITDA margin expansion offers strong justification for sustained expansion in P/E multiples. Joint ventures in Pune and Kanpur also offer an improved outlook on both volumes and margins. Our Sep'20 DCF-based target price remains unchanged at Rs 455. Maintain BUY.

FIG 7 - VALUATION SUMMARY

Valuation parameters	Value (Rs mn)
PV of FCF	20,588
PV of terminal value	239,102
Enterprise Value	259,690
Less: Net Debt	(22,975)
Equity value	282,665
NPV - IGL share (Rs)	404
NPV - MNGL (Rs)	35
NPV - CUPGL (Rs)	18
Consolidated NPV (Rs)	455

Source: BOBCAPS Research

FIG 8 - VALUATION SENSITIVITY

				WACC		
	(Rs)	9.0%	9.5%	10.2%	10.5%	11.0%
‡	6.0%	502	417	347	321	291
- grow	7.0%	630	492	390	355	316
Terminal growth	8.0%	886	618	455	403	350
Ē	9.0%	1,654	868	556	475	397
	9.5%	nm	1,619	745	595	467

Source: BOBCAPS Research

FIG 9 - RELATIVE STOCK PERFORMANCE



Source: NSE

INDRAPRASTHA GAS



Key risks

- Lower-than-expected margins FY20-22.
- Impact from PNGRB concept paper (read our analysis here) that paves the way for competition in existing areas, as tariff calculations remain uncertain
- Below-expected volume growth for CNG and PNG



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue	45,921	57,648	65,585	77,866	91,746
EBITDA	11,144	12,570	15,020	16,919	19,417
Depreciation	(1,813)	(2,011)	(2,435)	(2,767)	(3,080)
EBIT	9,331	10,559	12,585	14,151	16,337
Net interest income/(expenses)	(17)	(21)	(21)	0	0
Other income/(expenses)	926	1,462	1,182	1,931	3,416
EBT	10,241	12,000	13,747	16,083	19,753
Income taxes	(3,742)	(4,272)	(3,486)	(4,065)	(4,982)
Min. int./Inc. from associates	719	1,011	1,135	1,284	1,439
Reported net profit	7,217	8,739	11,396	13,302	16,210
Adjusted net profit	7,217	8,739	11,396	13,302	16,210

Balance Sheet

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Accounts payables	3,386	4,885	3,073	3,769	4,537
Other current liabilities	2,930	635	635	635	635
Provisions	137	206	206	206	206
Other liabilities	8,042	10,167	11,743	13,481	15,476
Equity capital	1,400	1,400	1,400	1,400	1,400
Reserves & surplus	35,070	42,503	52,588	64,580	79,479
Shareholders' fund	36,470	43,903	53,988	65,980	80,879
Total liabilities and equities	50,965	59,795	69,645	84,070	101,733
Cash and cash eq.	5,580	4,693	10,899	19,996	31,867
Accounts receivables	2,261	2,215	3,594	4,267	5,027
Inventories	524	509	898	1,067	1,257
Other current assets	1,259	594	1,194	1,794	2,394
Investments	13,160	17,779	15,440	15,440	15,440
Net fixed assets	24,320	29,224	34,595	38,180	42,088
CWIP	3,860	4,781	3,025	3,328	3,660
Total assets	50,965	59,795	69,645	84,070	101,733



Cash Flows

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net income + Depreciation	8,908	10,832	13,831	16,069	19,290
Changes in working capital	1,382	1,559	(3,579)	(146)	(182)
Other operating cash flows	(354)	(893)	(206)	(793)	(2,021)
Cash flow from operations	9,936	11,498	10,045	15,131	17,087
Capital expenditures	(5,182)	(7,917)	(6,050)	(6,655)	(7,321)
Change in investments	(5,321)	(4,619)	2,340	0	0
Other investing cash flows	926	1,462	1,182	1,931	3,416
Cash flow from investing	(9,576)	(11,075)	(2,528)	(4,724)	(3,905)
Dividends paid	(1,311)	(1,311)	(1,311)	(1,311)	(1,311)
Other financing cash flows	445	0	0	0	0
Cash flow from financing	(866)	(1,311)	(1,311)	(1,311)	(1,311)
Changes in cash and cash eq.	(506)	(887)	6,206	9,096	11,871
Closing cash and cash eq.	5,580	4,693	10,899	19,996	31,867

Per Share

Y/E 31 Mar (Rs)	FY18A	FY19A	FY20E	FY21E	FY22E
Reported EPS	10.3	12.5	16.3	19.0	23.2
Adjusted EPS	10.3	12.5	16.3	19.0	23.2
Dividend per share	1.6	1.6	1.6	1.6	1.6
Book value per share	52.1	62.7	77.1	94.3	115.5

Valuations Ratios

Y/E 31 Mar (x)	FY18A	FY19A	FY20E	FY21E	FY22E
EV/Sales	5.9	4.7	4.1	3.4	2.8
EV/EBITDA	24.2	21.5	18.0	15.6	13.1
Adjusted P/E	38.1	31.5	24.2	20.7	17.0
P/BV	7.5	6.3	5.1	4.2	3.4

DuPont Analysis

Y/E 31 Mar (%)	FY18A	FY19A	FY20E	FY21E	FY22E
Tax burden (Net profit/PBT)	70.5	72.8	82.9	82.7	82.1
Interest burden (PBT/EBIT)	109.7	113.6	109.2	113.6	120.9
EBIT margin (EBIT/Revenue)	20.3	18.3	19.2	18.2	17.8
Asset turnover (Revenue/Avg TA)	98.9	104.1	101.3	101.3	98.8
Leverage (Avg TA/Avg Equity)	1.4	1.4	1.3	1.3	1.3
Adjusted ROAE	21.7	21.7	23.3	22.2	22.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
YoY growth (%)					
Revenue	20.4	25.5	13.8	18.7	17.8
EBITDA	15.6	12.8	19.5	12.6	14.8
Adjusted EPS	19.0	21.1	30.4	16.7	21.9
Profitability & Return ratios (%)					
EBITDA margin	24.3	21.8	22.9	21.7	21.2
EBIT margin	20.3	18.3	19.2	18.2	17.8
Adjusted profit margin	15.7	15.2	17.4	17.1	17.7
Adjusted ROAE	21.7	21.7	23.3	22.2	22.1
ROCE	17.8	16.9	19.2	17.6	16.6
Working capital days (days)					
Receivables	17	14	16	18	18
Inventory	8	6	7	8	8
Payables	32	33	29	20	21
Ratios (x)					
Gross asset turnover	1.2	1.3	1.3	1.3	1.4
Current ratio	1.5	1.4	4.2	5.9	7.5
Net interest coverage ratio	552.1	515.1	613.9	0.0	0.0
Adjusted debt/equity	(0.2)	(0.1)	(0.2)	(0.3)	(0.4)



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: INDRAPRASTHA GAS (IGL IN)



B - Buy, A - Add, R - Reduce, S - Sell, H - Hold

Rating distribution

As of 31 October 2019, out of 79 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 48 have BUY ratings, 18 are rated ADD, 7 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

INDRAPRASTHA GAS



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.